The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures

Withdrawn before enrolling · Phase 4 · Has a placebo group

Conditions studied: Hip Fracture, Blood Loss

In brief

The goal of this study is to determine if the use of tranexamic acid, a safe and effective antifibrinolytic, in patients with intertrochanteric hip fractures will result in a reduction in blood transfusion rates. Treatment will be administered pre-operatively as well as at the time of surgical incision. The primary outcome will be need for blood transfusion. Secondary outcomes will include calculated perioperative blood loss, length of stay, cost of inpatient care, and rate of adverse events, including DVT, PE, infection, MI, cerebrovascular event, need for re-hospitalization or re-operation and 30 day mortality.

Key facts

Study ID

NCT01940536

Run by

Hospital for Special Surgery, New York

People needed

0

Starts

2015-12-01

Expected to finish

2019-12-01

Last updated by the study team

2017-03-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Intertrochanteric Hip Fracture
• Age >18

You may not qualify if…

• Preoperative use of anticoagulant (Clopidogrel, Warfarin, Enoxaparin, Fondaparinux, Rivaroxaban
• Allergy to Tranexamic Acid
• History of intracranial hemorrhage or significant GI or retroperitoneal bleed requiring hospitalization
• History of thromboembolic event (Stroke, Deep Vein Thrombosis, Pulmonary Embolism)
• History of cirrhosis or evidence of hepatic (AST/ALT >60) or renal dysfunction (Cr >1.5 or GFR <30)
• Coronary stents or prior diagnosis of CAD
• Color blindness

Where it is running

• New York Presbyterian Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.